The experiments in this proposal are based on the hypothesis that low serum ionized calcium decreases the synthesis of CGRP, which is a vasodilator, and by reducing that vasodilator, the level of blood pressure rises and contributes to hypertension. Secondly, the change in 1,25-vitamin D3 modulates neuronal CGRP synthesis such that increasing 1,25-D decreases CGRP neuronal content. This hypothesis is based on a current hypothesis that low calcium contributes to hypertension and offers a mechanism for this finding. Preliminary work by the investigator and his co-workers have demonstrated immunocytochemical distribution of CGRP in the spinal cord of rats. The levels of staining increase with increasing calcium diet. To test this more thoroughly, Dr. Dipette proposes to first infuse calcium chloride i.v. and measure the levels of immunocytochemical CGRP content in the spinal cord. Secondly, EGTA will be infused to reduce the levels of calcium. Third, CGRP mRNA levels will be measured in the dorsal root ganglia following chronic administration of 1,25-D. It is hypothesized that the changes in CGRP neuronal content, in response to dietary calcium increases, are due to changes in synthesis and release, rather than in storage. To test this, they will quantify CGRP mRNA by dot blot analysis and immunocytochemistry. The studies will be carried out in normotensive animals and in DOCA-salt rats to test the hypothesis that CGRP is more sensitive in low renin sodium dependent hypertension.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL044277-01A1
Application #
3363018
Study Section
Experimental Cardiovascular Sciences Study Section (ECS)
Project Start
1991-09-30
Project End
1994-09-29
Budget Start
1991-09-30
Budget End
1992-09-29
Support Year
1
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
Schools of Medicine
DUNS #
041367053
City
Galveston
State
TX
Country
United States
Zip Code
77555
Supowit, Scott C; Rao, Arundhati; Bowers, Mark C et al. (2005) Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 45:109-14
Bowers, Mark C; Katki, Khurshed A; Rao, Arundhati et al. (2005) Role of calcitonin gene-related peptide in hypertension-induced renal damage. Hypertension 46:51-7
Supowit, S C; Ethridge, R T; Zhao, H et al. (2005) Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol 289:H1169-75
Katki, Khurshed A; Supowit, Scott C; DiPette, Donald J (2002) Substance P in subtotal nephrectomy-salt hypertension. Hypertension 39:389-93
Watson, R E; Supowit, S C; Zhao, H et al. (2002) Role of sensory nervous system vasoactive peptides in hypertension. Braz J Med Biol Res 35:1033-45
Supowit, S C; Zhao, H; DiPette, D J (2001) Nerve growth factor enhances calcitonin gene-related peptide expression in the spontaneously hypertensive rat. Hypertension 37:728-32
Supowit, S C; Zhao, H; Wang, D H et al. (2001) Omapatrilat in subtotal nephrectomy-salt hypertension: role of calcitonin gene-related peptide. Hypertension 38:697-700
Katki, K A; Supowit, S C; DiPette, D J (2001) Role of calcitonin gene-related peptide and substance P in Dahl-salt hypertension. Hypertension 38:679-82
Greifenkamp, J D; DiPette, D J (1999) Adrenal medulla. Curr Hypertens Rep 1:241-5
Supowit, S C; Hallman, D M; Zhao, H et al. (1998) Alpha 2-adrenergic receptor activation inhibits calcitonin gene-related peptide expression in cultured dorsal root ganglia neurons. Brain Res 782:184-93

Showing the most recent 10 out of 16 publications